20 articles
Hone Health integrates BodySpec DEXA scans into its longevity platform, linking body composition data with hormone and metabolic markers for smarter care.
Immorta Bio is using AI to move beyond disease treatment toward restoring youthful biology by clearing senescent cells and reviving stem cells.
Serif Biomedicines aims to create a new drug class combining mRNA and gene therapy benefits, targeting rare diseases and immune reprogramming.
Behavior-change app Noom expands beyond weight loss into longevity by acquiring a pharmacy to combine habit coaching with prescription treatments.
Protuoso Biosciences raises $9.5M to build AI-engineered therapies that tackle multiple disease mechanisms simultaneously in one molecule.
Immorta Bio combines senolytics and stem cell revival with AI to achieve 70%+ lifespan extension in animal models.
A dual therapy clearing senescent cells and restoring stem cell function dramatically extended mouse lifespan in a new preclinical study.
Noom's free GLP-1 Companion program targets muscle loss, side effects, and habit formation to extend results beyond medication.
NorthStrive Biosciences files patents targeting muscle loss — a major side effect of GLP-1 obesity drugs — using peptide and microbiome tech.
Mountain View biotech's RLS-1496 becomes first GPX4-targeting senolytic to enter human trials, using AI platform to eliminate aging cells.
Seragon's SRN-901 outperformed rapamycin in aged mice, boosting median lifespan 33% and reducing frailty and tumor incidence.
Cyclana Bio's 500-patient PEMP study collects biopsies and menstrual fluid to uncover what drives endometriosis and identify new treatments.
Generation Lab's updated test measures 460+ biomarkers with separate male and female analyses, tracking organ aging and treatment response.
Gene therapies and exon-skipping drugs for Duchenne and myotonic dystrophy are nearing FDA submission, with launches potentially by 2027.
Swiss partnership launches cellular avatars that predict immune responses and aging patterns using AI-powered modeling.
NorthStrive Biosciences patents two muscle-preserving compounds targeting sarcopenia and GLP-1-related muscle loss in humans.
A new longevity startup secures seed funding to develop exosome-based therapies targeting osteoarthritis, skin repair, and joint diagnostics.
Early data show sustained telomere lengthening in blood cells, while a new licensing deal advances a dystrophin therapy for Duchenne muscular dystrophy.
A new AI-powered platform combines genetics, hormones, and lifestyle data to assess 130+ female-specific conditions before they worsen.
Istesso launches a clinical trial of leramistat, a regenerative therapy targeting sarcopenia — the muscle loss affecting 1 in 3 adults over 60.
